Skip to content
Disclosery

Column Group LLC

Follow

13F filer, CIK 1833486, San Francisco, CA

Column Group LLC reported $100,706,873 across 3 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-18.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-227853

Period
2026-03-31
Reported value
$101M
Holdings
3
Top 10 weight
100%
New
0
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
Surrozen, Inc.added+65,600$1.91M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TNYAexited-9,400,290-$6.69M
RAPT THERAPEUTICS INCexited-156,270-$5.29M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001193125-26-227853, largest first. % of portfolio is the value over $100,706,873, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
Surrozen, Inc.Surrozen, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 810,088 shares; 2024Q4: 810,088 shares; 2025Q1: 1,499,773 shares; 2025Q2: 1,499,773 shares; 2025Q3: 1,499,773 shares; 2025Q4: 1,851,350 shares; 2026Q1: 1,916,950 shares 1,916,950$55.8M55.45%+65,600
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,540,777 shares; 2024Q4: 3,540,777 shares; 2025Q1: 3,540,777 shares; 2025Q2: 3,540,777 shares; 2025Q3: 3,540,777 shares; 2025Q4: 3,540,777 shares; 2026Q1: 3,540,777 shares 3,540,777$44.9M44.55%0Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 46 shares; 2024Q4: 46 shares; 2025Q1: 46 shares; 2025Q2: 46 shares; 2025Q3: 46 shares; 2025Q4: 46 shares; 2026Q1: 46 shares 46$4.47K<0.01%0Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TNYATENAYA THERAPEUTICS INC9,400,290$6.69Mshares
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC156,270$5.29Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-227853 base2026-05-18acceptance time not in the bulk data set